Aquestive Therapeutics Financial Ratios
NASDAQ: AQSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
4.78+0.02 (+0.42%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aquestive Therapeutics ratio analysis
Aquestive Therapeutics earned a net margin of -188.1% in FY 2025, down from -76.7% a year earlier. Gross margin was 58.3% compared with a median of 61.3% over the prior 5 years. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Aquestive Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 15.48 | 5.39 | 2.45 | 0.92 | 2.91 | 3.93 | 2.82 | 2.45 | — |
| Price / book | — | — | — | — | — | — | — | 16.37 | — |
| Gross margin | 58.3% | 69.0% | 58.8% | 59.3% | — | 71.7% | 61.3% | — | — |
| Operating margin | -159.5% | -53.5% | -29.9% | -88.2% | -68.2% | -93.6% | -100.1% | -72.6% | -0.2% |
| Net margin | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | -121.7% | -125.9% | -91.0% | -13.4% |
| Free cash flow margin | -119.0% | -62.4% | -14.6% | -22.7% | -66.7% | -100.3% | -115.7% | -22.0% | 5.6% |
| Return on equity (ROE) | — | — | — | — | — | — | — | -608.9% | — |
| Return on assets (ROA) | -52.2% | -43.5% | -13.7% | -95.3% | -113.8% | -88.7% | -84.4% | -70.7% | -20.7% |
| Current ratio | 3.14 | 4.68 | 2.24 | 1.01 | 2.15 | 2.11 | 3.68 | 2.25 | 1.83 |
| Revenue growth | -22.6% | 13.8% | 6.1% | -6.2% | 10.9% | -12.8% | -22.0% | 0.8% | — |